Melanoma Posts on Medivizor
Navigation Menu

Melanoma Posts on Medivizor

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Posted by on Oct 17, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to investigate the safety and effectiveness of immunotherapy drug tebentafusp in previously untreated advanced uveal melanoma. The study showed that tebentafusp is effective and improved the overall survival in patients with uveal melanoma. Some background Melanoma is an aggressive kind of skin cancer. Uveal melanoma...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Melanoma | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the...

Read More

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Posted by on Sep 17, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects. Some background...

Read More

What are the most common skin-related side effects of immune therapy for patients with melanoma?

What are the most common skin-related side effects of immune therapy for patients with melanoma?

Posted by on Sep 12, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the skin-related side effects of immune checkpoint inhibitors in the treatment of melanoma. It found that the most common side effects were mild-to-moderate itching, rash, and vitiligo (loss of skin pigment).   Some background Immune checkpoint inhibitors (ICIs) are a type of immune therapy used to...

Read More

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Posted by on Sep 5, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of triple combination therapy with immune and targeted therapies in patients with stage III-IV melanoma. The data showed that triple combination therapy was associated with increased survival benefits with manageable side effects for these patients. Some background Melanoma is an...

Read More

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Read More

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

Posted by on Aug 8, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg...

Read More

Evaluating the long-term outcomes of cobimetinib plus vemurafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the long-term outcomes of cobimetinib plus vemurafenib in patients with BRAF-mutated advanced melanoma.

Posted by on Aug 7, 2021 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) and cobimetinib (Cotellic) in patients with previously untreated BRAF-mutated advanced melanoma. The data showed that the combination was safe and effective over the long term. Some background Melanoma is an aggressive...

Read More

Is a skin rash associated with the treatment response to vemurafenib and cobimetinib in patients with advanced melanoma?

Is a skin rash associated with the treatment response to vemurafenib and cobimetinib in patients with advanced melanoma?

Posted by on Jul 31, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to investigate the frequency and severity of skin rash-like symptoms known as exanthema and its relationship with treatment outcome with vemurafenib (Zelboraf) alone or vemurafenib combined with cobimetinib (Cotellic) in patients with advanced melanoma. The study showed that the appearance of exanthema within 6 weeks of...

Read More

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Posted by on Jul 24, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...

Read More

Is pembrolizumab plus ipilimumab combination therapy safe and effective for the treatment of advanced melanoma after failure of anti-PD-1/L1 therapy?

Is pembrolizumab plus ipilimumab combination therapy safe and effective for the treatment of advanced melanoma after failure of anti-PD-1/L1 therapy?

Posted by on Jul 11, 2021 in Melanoma | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of combining pembrolizumab (PEM; Keytruda)) and ipilimumab (IPI; Yervoy) for the treatment of advanced-stage melanoma in patients that have progressed after previous PD-1/L1 therapy. The study concluded that this combination was well tolerated and improved the...

Read More